Congress passed pharmacy benefit manager (PBM) reform, but most drug-cost protections do not start until 2028–2029. For clinical trial and paid-research seekers, that delay means counter costs and coverage gaps stay in place while you search. A PBM is the middleman that negotiates drug prices and rebates between makers, plans, and pharmacies. The new federal law changes how those rebates and fees flow, yet the start dates stretch years ahead.
Official resources:
- Register through FDA’s official page — Use this page to review requirements and register directly.
- Read the original report from House — Use this primary source to review the complete report.
Table of Contents
- What did Congress actually change?
- Why does 2028 feel like a delay?
- Who waits longest at the counter?
- What should research volunteers do now?
What did Congress actually change?
The law is H.R. 7148, the Consolidated Appropriations Act, 2026, signed Feb. 3, 2026.
Pharmacy Times reported that it codified landmark PBM reforms from the PBM Reform Act of 2025 for Medicare and commercial plans in the Pharmacy Times report. The Mintz law analysis explains that PBMs must remit full rebates and fees to plan clients quarterly, disclose rebates, allow annual audits, and delink Part D pay from drug prices, with most commercial and Part D reforms taking effect in 2028–2029 in the Mintz analysis. In plain terms, the plan—not the PBM—keeps the rebate money. PBM pay shifts toward flat service fees rather than a share of the drug price.
Why does 2028 feel like a delay?
The delay is implementation timing, not repeal. Any-willing-pharmacy standards apply for plan year 2029 after a 2027 information request and a 2028 final rule. Federal rulemaking must fill in the details first. CMS issued proposed rule CMS-4214-P on Oct.
16, 2026, published Oct. 20, to limit Part D PBM pay to flat, fair-market-value fees from 2028 and mandate full rebate pass-through, according to the Crowell and Moring alert. That leaves a two-year gap between signing and savings. Plans, pharmacies, and vendors must update contracts, reporting systems, and audits before patients see broad effects.
Who waits longest at the counter?
House Energy and Commerce summaries describe three groups watching the clock: patients paying at the counter, independent pharmacies seeking reasonable contracts and essential-pharmacy protections, and employer plans awaiting semiannual spending and spread-pricing reports. Independent pharmacies want fairer contract terms and network access. Employer plans want clearer data on where drug dollars go.
Other action is still pending or separate. A 2026 PharmExec review notes H.R. 6610 was ordered reported in July 2026 but not enacted, while FTC insulin-pricing settlements with large PBMs added rebate and formulary limits outside the new law.
What should research volunteers do now?
Protections depend on unfinished CMS and Labor Department guidance and start no earlier than 2028, Barclay Damon notes. Medicare pharmacist-service payment expansion also remains unaddressed. That means trial costs need the same careful check this year as last year.
The FDA directs patients to search ClinicalTrials.gov for recruiting studies in the FDA patient page. Use that listing to screen fit before you contact a site: Distance, insurance gaps for routine costs, and hidden costs still block enrollment. Ask the study contact to put cost coverage in writing before you enroll.
- Filter by condition, location, age, and key eligibility factors
- Ask who pays routine-care costs and what the study covers
- Ask about travel, parking, childcare, time off work, and follow-up visits
